```json
{
"content": [
{
"type": "paragraph",
"content": "Insulin aspart is a rapid-acting human insulin analog used to manage blood glucose levels in patients with diabetes. As a critical component of diabetes care, the insulin aspart market size is projected to grow significantly, driven by rising disease prevalence and innovations in biologics. This market forecast, spanning 2021–2033, underscores industry expansion amid evolving therapeutic demand and technological advancements."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["Type 1 Diabetes", "Type 2 Diabetes", "Other Indications"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[450, 470, 490, 510, 530, 550, 570, 590, 610, 630, 650, 670, 690], // Type 1 Diabetes
[700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940], // Type 2 Diabetes
[150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270] // Other Indications
]
}
},
{
"type": "paragraph",
"content": "The global insulin aspart market size reached $1.5 billion in 2026, reflecting a 6.5% CAGR from 2026 to 2033. Macro drivers include the escalating prevalence of Type 1 and Type 2 diabetes, supported by the World Health Organization’s 2023 report estimating 536 million adults with diabetes globally. Key forces shaping the industry include advancements in biosimilar production, regulatory approvals accelerating drug accessibility, and patient preference for rapid-acting insulin formulations. North America remains the largest region due to high diabetes incidence and robust healthcare infrastructure, while Asia-Pacific is the fastest-growing market, fueled by rising awareness and expanding biopharma investments."
}
]
}
```
